Aldeyra The
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALDX research report →
About the company
Aldeyra Therapeutics, Inc. , a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.
- CEO
- Todd C. Brady
- IPO
- 2014
- Employees
- 8
- HQ
- Lexington, MA, US
Price Chart
- Market Cap
- $136.93M
- P/E
- -5.00
- P/S
- 0.00
- P/B
- 3.25
- EV/EBITDA
- -3.47
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -57.34%
- ROIC
- -49.22%
- Revenue
- $0 · 0.00%
- Net Income
- $-33,846,661 · 39.40%
- EPS
- $-0.56 · 40.43%
- Op Income
- $-35,265,206
- FCF YoY
- 22.83%
- 52W High
- $6.17
- 52W Low
- $1.07
- 50D MA
- $1.75
- 200D MA
- $3.81
- Beta
- 1.19
- Avg Volume
- 1.40M
Get TickerSpark's AI analysis on ALDX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 9, 26 | Miller-Rich Nancy | other | 70,000 |
| Jun 9, 26 | Miller-Rich Nancy | other | 3,318 |
| Jun 9, 26 | DOUGLAS RICHARD | other | 70,000 |
| Jun 9, 26 | DOUGLAS RICHARD | other | 19,909 |
| Jun 9, 26 | DOUGLAS RICHARD | other | 2,323 |
| Jun 9, 26 | Phillips Gary M. | other | 70,000 |
| Jun 9, 26 | Phillips Gary M. | other | 6,636 |
| Jun 9, 26 | Phillips Gary M. | other | 4,977 |
| Jun 9, 26 | Clark William D | other | 70,000 |
| Jun 9, 26 | Clark William D | other | 2,323 |
Our ALDX coverage
Recent articles, reports, and earnings notes.
No research on ALDX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALDX report →Similar companies
Peers in the same neighborhood.